
Commentary|Podcasts|July 15, 2025
COBRRA Trial Results Raise Questions About VTE Management
The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Advertisement
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5


























